Liver proteomics in progressive alcoholic steatosis

Toxicology and Applied Pharmacology

Volumn 266, Issue 3, 2013, Pages 470-480

  Fernando, Harshica ^a   Wiktorowicz, John E ^a   Soman, Kizhake V ^a   Kaphalia, Bhupendra S ^a   Khan, M Firoze ^a   Shakeel Ansari, G A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alcoholic liver disease; Multivariate regression adaptive splines; Proteomics; Steatohepatitis; Steatosis; Two dimensional gel electrophoresis

Indexed keywords

ALCOHOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; BETAINE HOMOCYSTEINE METHYLTRANSFERASE; DOPACHROME TAUTOMERASE; HOMOCYSTEINE; LIPID; METHIONINE; PEROXIREDOXIN 1;

ADAPTATION; ALCOHOL METABOLISM; ALCOHOLIC FATTY LIVER; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DOWN REGULATION; FEEDING; LIPID METABOLISM; LIVER PROTECTION; MALE; MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLASMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RAT; SERUM; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ETHANOL; FATTY LIVER, ALCOHOLIC; GENE EXPRESSION REGULATION; MALE; PROTEOMICS; RATS; RATS, INBRED F344; REGRESSION ANALYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

ANIMALIA; RATTUS;

EID: 84872019386     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.11.017     Document Type: Article

References (50)

1. Arteel G., Marsano L., Mendez C., Bentley F., McClain C.J. Advances in alcoholic liver disease. Best Pract. Res. Clin. Gastroenterol. 2003, 17:625-647.
2. Banerjee A., Russell W.K., Jayaraman A., Ramaiah S.K. Identification of proteins to predict the molecular basis for the observed gender susceptibility in a rat model of alcoholic steatohepatitis by 2-D gel proteomics. Proteomics 2008, 8:4327-4337.
3. Bell L.N., Theodorakis J.L., Vuppalanchi R., Saxena R., Bemis K.G., Wang M., Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010, 51:111-120.
4. Bergheim I., McClain C.J., Arteel G.E. Treatment of alcoholic liver disease. Dig. Dis. 2005, 23:275-284.
5. Brasier A.R., Garcia J., Wiktorowicz J.E., Spratt H.M., Comach G., Ju H., Recinos A., Soman K., Forshey B.M., Halsey E.S., Blair P.J., Rocha C., Bazan I., Victor S.S., Wu Z., Stafford S., Watts D., Morrison A.C., Scott T.W., Kochel T.J., Gr V.D.F.W. Discovery proteomics and nonparametric modeling pipeline in the development of a candidate biomarker panel for dengue hemorrhagic fever. Clin. Transl. Sci. 2012, 5:8-20.
6. Bravo E., Palleschi S., Aspichueta P., Buque X., Rossi B., Cano A., Napolitano M., Ochoa B., Botham K.M. High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the transsulphuration pathway. Lipids Health Dis. 2011, 10:60.
7. Calligaris D., Villard C., Lafitte D. Advances in top-down proteomics for disease biomarker discovery. J. Proteomics 2011, 74:920-934.
8. Ciuclan D., Ehnert S., IIkavets I., Weng H., Gaitantzi H., Tsukamoto H., Ueberham E., Meindl-Beinker N., Breitkopf K., Dooley S. TGF-beta enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I. J. Hepatol. 2010, 52:407-416.
9. Coleman A.M., Rendon B.E., Zhao M., Qian M.W., Bucala R., Xin D., Mitchell R.A. Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, d-dopachrome tautomerase. J. Immunol. 2008, 181:2330-2337.
10. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
11. Fernando H., Kondraganti S., Bhopale K.K., Volk D.E., Neerathilingam M., Kaphalia B.S., Luxon B.A., Boor P.J., Shakeel Ansari G.A. (1)H and (31)P NMR lipidome of ethanol-induced fatty liver. Alcohol. Clin. Exp. Res. 2010, 34:1937-1947.
12. Fernando H., Bhopale K.K., Kondraganti S., Kaphalia B.S., Shakeel Ansari G.A. Lipidomic changes in rat liver after long-term exposure to ethanol. Toxicol. Appl. Pharmacol. 2011, 255:127-137.
13. Fernando H., Bhopale K.K., Boor P.J., Ansari G.A.S., Kaphalia B.S. Hepatic lipid profiling of deer mice fed ethanol using (1)H and (31)P NMR spectroscopy: a dose-dependent subchronic study. Toxicol. Appl. Pharmacol. 2012, 264:361-369.
14. Freeman W.M., Vrana K.E. Future prospects for biomarkers of alcohol consumption and alcohol-induced disorders. Alcohol. Clin. Exp. Res. 2010, 34:946-954.
15. Freeman W.M., Salzberg A.C., Gonzales S.W., Grant K.A., Vrana K.E. Classification of alcohol abuse by plasma protein biomarkers. Biol. Psychiatry 2010, 68:219-222.
16. French S.W. Alcoholic hepatitis: inflammatory cell-mediated hepatocellular injury. Alcohol 2002, 27:43-46.
17. Friedman J.H. Multivariate adaptive regression splines. Ann. Stat. 1991, 19:1-67.
18. Galasko D. Biomarkers for Alzheimer's disease-clinical needs and application. J. Alzheimers Dis. 2005, 8:339-346.
19. Gomperts B.N., Spira A., Massion P.P., Walser T.C., Wistuba I.I., Minna J.D., Dubinett S.M. Evolving concepts in lung carcinogenesis. Semin. Respir. Crit. Care Med. 2011, 32:32-43.
20. Haber H., Jahn H., Ehrenreich H., Melzig M.F. Assay of salsolinol in peripheral blood mononuclear cells of alcoholics and healthy subjects by gas chromatography-mass spectrometry. Addict. Biol. 2002, 7:403-407.
21. Helander A. Biological markers in alcoholism. J. Neural. Transm. Suppl. 2003, 15-32.
22. (10/01/12). http://www.matrixscience.com.
23. Husson A., Brasse-Lagnel C., Fairand A., Renouf S., Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur. J. Biochem. 2003, 270:1887-1899.
24. Iwata T., Taniguchi H., Kuwajima M., Taniguchi T., Okuda Y., Sukeno A., Ishimoto K., Mizusawa N., Yoshimoto K. The action of d-dopachrome tautomerase as an adipokine in adipocyte lipid metabolism. PLoS One 2012, 7:e33402.
25. Ji C. Mechanisms of alcohol-induced endoplasmic reticulum stress and organ injuries. Biochem. Res. Int. 2012, 2012:216450.
26. Kanaujiya J.K., Lochab S., Pal P., Christopeit M., Singh S.M., Sanyal S., Behre G., Trivedi A.K. Proteomic approaches in myeloid leukemia. Electrophoresis 2011, 32:357-367.
27. Koteish A., Diehl A.M. Animal models of steatosis. Semin. Liver Dis. 2001, 21:89-104.
28. Koteish A., Diehl A.M. Animal models of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2002, 16:679-690.
29. Lieber C.S., DeCarli L.M. Liquid diet technique of ethanol administration: 1989 update. Alcohol Alcohol. 1989, 24:197-211.
30. Liu H., Jones B.E., Bradham C., Czaja M.J. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alpha. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G257-G266.
31. Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis. N. Engl. J. Med. 2009, 360:2758-2769.
32. MARS User Manua Salford Systems 2001.
33. Merk M., Zierow S., Leng L., Das R., Du X., Schulte W., Fan J., Lue H.Q., Chen Y.B., Xiong H.B., Chagnon F., Bernhagen J., Lolis E., Mor G., Lesur O., Bucala R. The d-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E577-E585.
34. Miranda-Mendez A., Lugo-Baruqui A., Armendariz-Borunda J. Molecular basis and current treatment for alcoholic liver disease. Int. J. Environ. Res. Public Health 2010, 7:1872-1888.
35. Nanji A.A. Role of different dietary fatty acids in the pathogenesis of experimental alcoholic liver disease. Alcohol 2004, 34:21-25.
36. Neuhold L.A., Guo Q.M., Alper J., Velazquez J.M. High-throughput proteomics for alcohol research. Alcohol. Clin. Exp. Res. 2004, 28:203-210.
37. Newton B.W., Russell W.K., Russell D.H., Ramaiah S.K., Jayaraman A. Liver proteome analysis in a rodent model of alcoholic steatosis. J. Proteome Res. 2009, 8:1663-1671.
38. Pais R., Pascale A., Fedchuck L., Charlotte F., Poynard T., Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin. Res. Hepatol. Gastroenterol. 2011, 35:23-28.
39. Rhee S.G., Chae H.Z., Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radical Biol. Med. 2005, 38:1543-1552.
40. Rodriguez-Suarez E., Duce A.M., Caballeria J., Arrieta F.M., Fernandez E., Gomara C., Alkorta N., Ariz U., Martinez-Chantar M.L., Lu S.C., Elortza F., Mato J.M. Non-alcoholic fatty liver disease proteomics. Proteomics Clin. Appl. 2010, 4:362-371.
41. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75:163-189.
42. Teli M.R., Day C.P., Burt A.D., Bennett M.K., James O.F.W. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995, 346:987-990.
43. Verrills N.M., Irwin J.A., Yan He X., Wood L.G., Powell H., Simpson J.L., McDonald V.M., Sim A., Gibson P.G. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011, 183:1633-1643.
44. Werstuck G.H., Lentz S.R., Dayal S., Hossain G.S., Sood S.K., Shi Y.Y., Zhou J., Maeda N., Krisans S.K., Malinow M.R., Austin R.C. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 2001, 107:1263-1273.
45. Witzmann F.A., Strother W.N. Proteomics and alcoholism. Int. Rev. Neurobiol. 2004, 61:189-214.
46. Wood Z.A., Schroder E., Harris J.R., Poole L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 2003, 28:32-40.
47. Wurst F.M., Kempter C., Metzger J., Seidl S., Alt A. Ethyl glucuronide: a marker of recent alcohol consumption with clinical and forensic implications. Alcohol 2000, 20:111-116.
48. Younossi Z.M., Baranova A., Ziegler K., Del Giacco L., Schlauch K., Born T.L., Elariny H., Gorreta F., VanMeter A., Younoszai A., Ong J.P., Goodman Z., Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42:665-674.
49. Zhang W., Chait B.T. ProFound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal. Chem. 2000, 72:2482-2489.
50. Zhihua L., Ma Y., Yang J., Qin H. Upregulated and downregulated proteins in hepatocellular carcinoma: a systematic review of proteomic profiling studies. OMICS 2011, 15:61-71.